About: Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019
Creator	Yang, Yi Li, Xin Li, Yan Lv, Ping Shi, Yuxin Zhou, Hua Luo, Pei Li, Zhao Shi, Y Zhang, Zhang, Jianchu Bai, Tao Ge, Yanyan Huang, Shilong Liu, Lancong Yang, Xuefeng Zhao, Xiaobo Zhao, ，xiaobo
Source	Elsevier; Medline; PMC
abstract	OBJECTIVES: The current diagnosis and medicines approach in coronavirus disease 2019 (COVID-19) does not reflect the heterogeneous characteristics of this disease. This study aims to find a new antiviral combination regimen by investigating the frequency of clinically relevant and objectively identified comorbidities, and the clustering of these clinical syndromes and varying results of treatment with antiviral drugs in patients hospitalized with severe COVID-19. METHODS: This study recruited 151 severe COVID-19 infection cases diagnosed in our hospital examination and illustrated the clinical potential during a consecutive 25-day medication period. Potential differences in disease severity and clinical characteristics, hematological profile, and current pharmacologic treatments (single agent, double or triple combinations, and the combined antiviral drugs plus Lianhua Qingwen) among comorbidity clusters were explored. RESULTS: Although disease severity was comparable among three clusters, it was markedly different in terms of laboratory test status. Coagulable abnormality was mainly present in cluster 1 and cluster 2. Other indicators were normal, except for a significant increase of neutrophils presented in cluster 2. Patients showed the most complicated haematological results in cluster 3, including severe coagulation abnormalities, leukocytosis, neutrophilic granulocytosis, and lymphopenia. Our results for the first time suggest that a quadruple combination therapy (Ribavirin, Lopinavir/ritonavir, Umifenovir, and Lianhua Qingwen) can be considered as a preferred treatment approach to severe COVID-19 patients. After treatment, abnormal coagulation and leukocyte had markedly improved with a better prognosis. CONCLUSION: This study expands the understanding of the co-occurrence of combination therapy in patients with COVID-19, which provides the probability of developing novel combined therapy. Furthermore, explore clinical trials of variable antivirus treatments based on subgroup analyses or on using subgroups in the selection criteria would be the next step.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1016/j.phrs.2020.105036
bibo:pmid	32565309
has license	no-cc
sha1sum (hex)	81029daf9ed03fce4c397d878d9a303c97aba834
schema:url	https://doi.org/10.1016/j.phrs.2020.105036
resource representing a document's title	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019
has PubMed Central identifier	PMC7301803
has PubMed identifier	32565309
schema:publication	Pharmacol Res
resource representing a document's body	covid:81029daf9ed03fce4c397d878d9a303c97aba834#body_text
is schema:about of	covid:arg/81029daf9ed03fce4c397d878d9a303c97aba834 named entity 'adults' named entity 'severe' named entity 'ribavirin' named entity 'D-dimer' named entity 'antiviral drugs' named entity 'human beings' named entity 'drug resistance' named entity 'D-dimer' named entity 'macrophages' named entity 'combination therapy' named entity 'RNA' named entity 'clinical investigations' named entity 'coronavirus disease 2019' named entity 'respiratory tract diseases' named entity 'MERS-CoV' named entity 'leukocyte' named entity 'COVID' named entity 'WBC' named entity 'COVID-19' named entity 'Union Hospital' named entity 'COVID' named entity 'SARS' named entity 'sodium chloride' named entity 'zoonotic' named entity 'cluster analysis' named entity 'influenza' named entity 'umifenovir' named entity 'single-stranded' named entity 'medical chart' named entity 'diabetes mellitus' named entity 'non-infectious' named entity 'COVID' named entity 'lymphocyte' named entity 'infection' named entity 'subgroup analysis' named entity 'antivirals' named entity 'oseltamivir' named entity 'Umifenovir' named entity 'neutrophil' named entity 'neutrophil' named entity 'drug treatment' named entity 'fever' named entity 'severe acute respiratory syndrome coronavirus' named entity 'antiviral' named entity 'complete blood count' named entity 'phenotypes' named entity 'RNA' named entity 'complete blood count' named entity 'WBC' named entity 'fever' named entity 'inflammation' named entity 'fixed-dose combination' named entity 'virions' named entity 'umifenovir' named entity 'pneumonia' named entity '19, 20' named entity 'Ribavirin' named entity 'avian influenza' named entity 'epidemic' named entity 'umifenovir' named entity 'COVID-19 outbreak' named entity 'viruses' named entity 'comorbidities'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software